

MEDICAL PRODUCT ALERT

DRAP ALERT NO. Nº I/S/4-25-35

SUBSTANDARD PRODUCTS DECLARED BY PROVINCIAL DRUG TESTING LABORATORIES.

Date: 07th April, 2025

Target Audience:

- National Regulatory Field Force of DRAP and Provincial Drug Control Departments.
- Healthcare Professionals (Physicians, Pharmacists & Nurses).
- General Public.

Alert Summary:

Directorate of Drug Control (DDC) Punjab has informed Drug Regulatory Authority of Pakistan that the samples of below mentioned products have been reported as 'Substandard'.

| S# | Product Name | Batch No. | Manufacturers | Remarks |
|----|---------------------------------------|-----------|-------------------------------------|--|
| 1. | Amekoran Injection Each 2mL contains: | | M/s Ameer Pharma (Pvt) Ltd, | 'Substandard' on the basis of visible |
| | Amikacin (as Sulphate)250mg | BK-019 | 23-Km, Sheikhupura Road, Lahore. | particulates. |
| | Reg. No. 053627 | | | |
| 2. | Ortizin Tablet | | M/s. Obsons | 'Substandard' with |
| | Each film coated tablet | | Pharmaceuticals, | regards to impurities. |
| | contains: Cetirizine | 24I268 | 209-S, Quaid-e-Azam | |
| | dihydrochloride10mg | 241208 | Industrial Estate, Kot | |
| | | | Lakhpat, Lahore. | |
| | Reg. No. 025405 | | | |
| 3. | AQUA-P Injection | | M/s. IPRAM International, | 'Substandard' on the |
| | Sterile water for | | Plot No. 26, St # S.S-3, | basis of visible particulate |
| | Injection 5ml | P-669 | National Industrial Zone, | matter. |
| | | | Rawat. | |
| | Reg. No. 034290 | | | |
| 4. | Injection Dorcip 100ml | | M/s. Trigon | 'Substandard' with |
| | Ciprofloxacin as | | Pharmaceuticals (Pvt) Ltd. | regards to visible |
| | lactate2mg/ml | DC-121 | 8-Km, Thokar Raiwind | particulates in injection |
| | | | Road, Lahore. | and Sterility Test. |
| | Reg. No. 046086 | | | - |









| 5. | Meclomine Tablet 500mcg Each film coated tablet contains: Mecobalamine500mcg Reg# 042601 | 8482 | M/s Alfalah Pharma (PVT) Ltd., 12-Km, Sheikhupura Road, Lahore. | 'Adulterated' as per section 3(a)(iv) of Drugs Act, 1976. |
|----|---|--------|---|---|
| 6. | Meclomine Tablet 500mcg Each film coated tablet contains: Mecobalamine500mcg Reg# 042601 | 8440 | M/s Alfalah Pharma (PVT) Ltd., 12-Km, Sheikhupura Road, Lahore. | 'Substandard' on the basis of Physical Description & Assay Test and 'Adulterated' as per section 3(a)(iv) of Drugs Act, 1976. |
| 7. | Injection Neocobal Mecobalamine 0.5mg/ml Reg# 071447 | S-2455 | M/s Pulse Pharmaceuticals (Pvt.) Ltd., Sua Aasil, Raiwind Road, Lahore. | 'Substandard' on the basis of Assay Test and 'Adulterated' as per Drugs Act, 1976. |

Risk Statement:

The use of substandard products can result in therapy failure, increasing the risk of complications, particularly in vulnerable groups such as immunocompromised individuals, as well as pediatric and geriatric population.

Action initiated: -

The field force of DRAP and Provincial Drug Control departments have been directed to immediately conduct market surveys for detection of presence and removal of mentioned batches from the market.

Advice for Pharmacies/Medical stores: -

All pharmacists and chemist working at distributions and pharmacies should **immediately check** their stocks and stop supplying mentioned products. The remaining stocks should be quarantined and returned to the supplier/company. Regulatory field force of all federating units (DRAP and Provincial Health Departments) should also increase surveillance in the market to ensure the effective recall of defective products(s).

Advice for Healthcare Professionals: -

DRAP requests increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by batches of mentioned products. Adverse reactions or quality problems experienced with the use of above mentioned product are to be reported to the National Pharmacovigilance Centre (NPC), DRAP using Adverse Event Reporting Form or online through this link. Further information of reporting problems to DRAP is available on this link.









Advice for Consumers/general public: -

Consumers should stop using products bearing the affected batch number(s) and shall contact to their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product, and report the incident to Drug Regulatory Authority of Pakistan/ National Pharmacovigilance Centre.



Drug Regulatory Authority of Pakistan محفوظ، موئثر اور معیاری اشیائے علاج







gsms@dra.gov.pk